TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05759715

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)

Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
Study: NCT02267707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study: NCT04756921

Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib 400mg po qd
Study: NCT01003938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT03961828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
Description: The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
Study: NCT01572051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone Calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material
Study: NCT01545193

Intervention type: OTHER
Intervention: Age and incidence of residual neuromuscular blockade
Description: An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade

Intervention type: OTHER
Intervention: Age and incidence of residual neuromuscular blockade
Description: An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
Study: NCT01780051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide/Metformin combination, Repaglinide, Metformin
Description: Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide/Metformin combination, Repaglinide, Metformin
Description: Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.
Study: NCT02550535

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous WT1 TCR transduced T cells
Description: Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
Study: NCT04904094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casting of the lower limb and homebased stretching exercise program.
Description: Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
Study: NCT00506376

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview that will take about 20 minutes to complete.
Study: NCT02827097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denogan and rectus sheath block
Description: administration of denogan and rectus sheath block with 0.375% ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denogan
Description: administration of denogan
Study: NCT03256396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP setting based on esophageal pressure measured
Description: PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
Study: NCT02974907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study: NCT03078608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program (administered via mobile app)
Description: Mobile app-based/online mindfulness meditation program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness meditation program (administered via mobile app)
Description: Mobile app-based/online mindfulness meditation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation (via mobile app)
Description: Mobile app-based/online progressive muscle relaxation program
Study: NCT02555137

Intervention type: OTHER
Intervention: 'prediction score' and 'rule-out criteria'
Description: The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
Study: NCT00774540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Ketorolac intraarticular
Description: Ketorolac intraarticular 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT04471116

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OMNi-BiOTiC® FLORA plus+
Description: OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
Study: NCT00503919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-spectral Digital Colposcopy (MDC)
Description: Use of a digital camera and a special light to take pictures of the cervix and vagina.
Study: NCT01677338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-uracil
Description: PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
Study: NCT06738511

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: Molecular signature using plasma sample

Intervention type: OTHER
Group type: OTHER
Intervention: stool sampling
Description: Stool sampling (by the participant)
Study: NCT01494857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
Study: NCT06738511

Intervention type: OTHER
Group type: OTHER
Intervention: colonoscopy
Description: Colonoscopy will be performed in the course of a screening programme
Study: NCT02256878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study: NCT03235492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartAlbu
Description: Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device
Study: NCT02232321

Intervention type: OTHER
Group type: OTHER
Intervention: PsA MDA
Study: NCT04394000

Intervention type: OTHER
Intervention: thromboprofylaxis protocol
Description: This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity

Intervention type: OTHER
Intervention: standard protocol
Description: This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
Study: NCT02944461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone 7.5 % gel
Description: Dapsone gel 7.5% applied once daily to truncal acne
Study: NCT02417480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow habitual, usual diet
Description: Participants will be asked to consume their habitual, usual diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow habitual, usual diet
Description: Participants will be asked to consume their habitual, usual diet.
Study: NCT02872142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albutein 5%
Description: Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma Exchange will be performed using albutein 5% as the replacement solution.
Study: NCT03156621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab SC Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab SC Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo SC Q2W
Study: NCT01266057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Starting dose of 200 mg by mouth every day for a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Starting dose of 200 mg by mouth every day for a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Starting dose of 2 mg by mouth every day for a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting dose of 200 mg by mouth per day for a 21 day cycle.
Study: NCT01694186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI insert

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Study: NCT00501943

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avonex (Interferon beta 1a)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex (Interferon beta 1a)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03016403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care Intervention
Description: The intervention delivered evidence-based CBT and stress management across eight counseling sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
Study: NCT05571163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Tablets
Study: NCT01008046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined N-acetyl cysteine -CC
Description: N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined metformin-CC
Description: Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Study: NCT00930332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone hydrochloride
Description: Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone hydrochloride
Description: Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: within 48 hours of registration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: within 48 hours of registration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: if required

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: if required
Study: NCT00576407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue for Implantation (CTTI)
Description: Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
Study: NCT01431573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake Therapy
Description: Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light box
Description: use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
Study: NCT00638079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate oral suspension 625 mg/5 mL
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate oral suspension 625 mg/5 mL
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
Study: NCT03952520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Approach (SA)
Description: The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Approach (TA)
Description: The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.